129779-30-2

Basic information

• Product Name: 1-BOC-3,5-DIMETHYL-PIPERAZINE
• Synonyms: (3R,5S)-3,5-DIMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-BOC-3,5-DIMETHYL-PIPERAZINE;1-BOC-CIS-3,5-DIMETHYL-PIPERAZINE;CIS-3,5-DIMETHYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;5-DiMethyl-piperazine-1-carboxylic acid tert-butyl ester;cis-3;1-Piperazinecarboxylic acid, 3,5-diMethyl-, 1,1-diMethylethyl ester, (3R,5S)-;(3R,5S)-rel-tert-Butyl 3,5-diMethylpiperazine-1-carboxylate
• CAS NO: 129779-30-2
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Mol File: 129779-30-2.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 279.7±15.0℃ (760 Torr)
• Flash Point: 123.0±20.4℃
• Appearance: /
• Density: 0.970±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.452
• Storage Temp.: -20°C
• PKA: 8.58±0.60(Predicted)
• CAS DataBase Reference: 1-BOC-3,5-DIMETHYL-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3,5-DIMETHYL-PIPERAZINE(129779-30-2)
• EPA Substance Registry System: 1-BOC-3,5-DIMETHYL-PIPERAZINE(129779-30-2)

Safety Data

• Hazard Codes: N
• Statements: 36/37/38-50
• Safety Statements: 26-61
• RIDADR: UN3077
• Hazardous Substances Data: 129779-30-2(Hazardous Substances Data)

Usage

Description

1-BOC-3,5-DIMETHYL-PIPERAZINE is a heterocyclic derivative that serves as a crucial pharmaceutical intermediate due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
1-BOC-3,5-DIMETHYL-PIPERAZINE is used as a pharmaceutical intermediate for the development of various drugs, particularly in the synthesis of 7-(3-(Piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives. These derivatives have been identified as highly potent, selective, and orally bioavailable PI3Kδ inhibitors, which play a significant role in the treatment of various diseases, including cancer and autoimmune disorders.
In the field of medicinal chemistry, 1-BOC-3,5-DIMETHYL-PIPERAZINE's unique structure allows for the creation of novel compounds with potential therapeutic applications, making it a valuable asset in drug discovery and development processes.

InChI:InChI=1/C11H22N2O2/c1-8-6-13(7-9(2)12-8)10(14)15-11(3,4)5/h8-9,12H,6-7H2,1-5H3/t8-,9+

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 21655-48-1 cis-2,6-dimethylpiperazine 
• 108-49-6 3,5-dimethylpiperazine 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 198895-89-5 4-benzyl-cis-3,5-dimethylpiperazine1-carboxylic acid tert-butyl ester 
• 1124214-79-4 (3S,5R)-tert-butyl 4-(3-(tert-butylcarbamoyl)benzyl)-3,5-dimethylpiperazine-1-carboxylate 
• 1124214-75-0 N-tert-Butyl-3-(((2S,6R)-4-(4-(3-cyclobutylureido)benzoyl)-2,6-dimethylpiperazin-1-yl)methyl)benzamide 2,2,2-trifluoroacetate 
• 1435953-66-4 (3S,5R)-4-(5-aminothiazolo[5,4-d]pyrimidin-7-yl)-N-(4-methoxyphenyl)-3,5-dimethyl piperazine-1-carboxamide 
• 129785-64-4 (pentachlorophenyl)-4--2,6-dimethylpiperazin-1-yl>-1,2,5-thiadiazol-3-carboxylate 

Relevant articles and documents

TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION

The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto- temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer including melanoma.

5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS

The present invention discloses compounds according to Formula (I), wherein R, R2, R3a, R3b, and Cy are as defined herein. The present invention discloses compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same and methods for the prophylaxis and/or treatment of inflammatory conditions and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.